Largest biotech companies in the United States by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Amgen leads the 20 biotech companies in the United States ranked by total liabilities, at NOK 799B, ahead of Gilead Sciences (NOK 355B) and Biogen (NOK 109.1B). Figures as of 20 Nov 2026, 12:29 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 20
- First
- AmgenNOK 799B
- Median
- NOK 5.7B
- Combined market value
- NOK 7.17T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Biotech▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | NOK 799B | NOK 2.31T | NOK 4,279.54 | 1.14% down | 30% up | ||
| 2 | Gilead SciencesGILD · Health Care | NOK 355B | NOK 2.01T | NOK 1,624.06 | 1.45% down | 31% up | ||
| 3 | BiogenBIIB · Health Care | NOK 109.1B | NOK 356.3B | NOK 2,410.10 | 1.70% down | 41% up | ||
| 4 | ModernaMRNA · Health Care | NOK 36B | NOK 786.6B | NOK 1,943.94 | 1.29% up | 740% up | ||
| 5 | Halozyme TherapeuticsHALO · Health Care | NOK 24.2B | NOK 103.4B | NOK 907.36 | 2.88% down | 32% up | ||
| 6 | Neurocrine BiosciencesNBIX · Health Care | NOK 13.4B | NOK 154.6B | NOK 1,527.12 | 3.85% down | 10% up | ||
| 7 | ImmunityBioIBRX · Health Care | NOK 9.8B | NOK 68.2B | NOK 64.07 | 1.94% down | 216% up | ||
| 8 | RepligenRGEN · Health Care | NOK 8.2B | NOK 106.2B | NOK 1,660.73 | 1.38% down | 5% up | ||
| 9 | Revolution MedicinesRVMD · Health Care | NOK 7.1B | NOK 336.3B | NOK 1,554.82 | 0.24% down | 125% up | ||
| 10 | ExelixisEXEL · Health Care | NOK 6.7B | NOK 156.7B | NOK 642.00 | 3.60% down | 55% up | ||
| 11 | Bio-TechneTECH · Health Care | NOK 4.7B | NOK 111.4B | NOK 709.00 | 0.07% down | 18% up | ||
| 12 | VaxcytePCVX · Health Care | NOK 3.1B | NOK 90.1B | NOK 569.15 | 0.27% down | 22% up | ||
| 13 | Adaptive BiotechnologiesADPT · Health Care | NOK 2.8B | NOK 44.3B | NOK 273.55 | 1.44% down | 51% up | ||
| 14 | Kodiak SciencesKOD · Health Care | NOK 1.9B | NOK 62.4B | NOK 954.76 | 0.09% up | 371% up | ||
| 15 | Twist BioscienceTWST · Health Care | NOK 1.6B | NOK 74.2B | NOK 1,088.56 | 4.07% down | 291% up | ||
| 16 | Kymera TherapeuticsKYMR · Health Care | NOK 1.6B | NOK 99.4B | NOK 1,164.34 | 1.44% down | 81% up | ||
| 17 | Scholar Rock HoldingSRRK · Health Care | NOK 1.5B | NOK 59.9B | NOK 491.23 | 4.94% up | 25% up | ||
| 18 | Krystal BiotechKRYS · Health Care | NOK 1.1B | NOK 91.3B | NOK 3,079.99 | 0.15% up | 49% up | ||
| 19 | ImmunovantIMVT · Health Care | NOK 1B | NOK 65.6B | NOK 317.15 | 1.96% down | 44% up | ||
| 20 | CG OncologyCGON · Health Care | NOK 380.2M | NOK 71.3B | NOK 798.72 | 2.38% up | 93% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 9.7524 NOK).
Questions and answers
Which biotech companies in the United States rank first by total liabilities?
Amgen (NOK 799B), Gilead Sciences (NOK 355B) and Biogen (NOK 109.1B) are the top three of the 20 biotech companies in the United States ranked by total liabilities as of 20 Nov 2026, 12:29 UTC.
How many biotech companies in the United States are in this ranking?
20 are ranked by total liabilities.
What are these biotech companies in the United States worth together?
The 20 biotech companies in the United States ranked by total liabilities have a combined market value of NOK 7.17T as of 20 Nov 2026, 12:29 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies in the United States by total liabilities”, data as of 20 November 2026. https://funkfolio.com/companies/category/biotech?country=united-states&by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.